University of Southern California


RFA-DK-18-017: Ancillary Studies to the NIDDK Inflammatory Bowel Disease Genetics Consortium (R01- Clinical Trial Optional)

Slots:                                                     1                             

Internal Deadline:                           Friday, October 19, 2018, 12pm PT

LOI:                                                        January 21, 2019                              

External Deadline:                          February 21, 2019 by 5:00 PM local time of applicant organization.

Award Information:                        Type:  Grant

Estimated Number of Awards: NIDDK intends to commit up to $1,000,000 in FY 2019 to fund up to 3 awards.

Anticipated Amount: Application budgets are limited to $200,000 direct costs per year.

Submission Process:                     PIs must submit their application as a Limited Submission through the Office of Research Application Portal:

Materials to submit:

Link to Award:                        

Who May Serve as PI:                    Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.


The NIDDK Inflammatory Bowel Disease Genetics Consortium (IBDGC), in collaboration with the International IBD Genetics Consortium, has identified about 200 susceptibility loci for IBD.  The IBDGC has recently been awarded renewed funding to identify causal genes and genetic variants within these loci, and to elucidate the mechanisms through which they contribute to the pathophysiology of IBD.  However, the IBDGC’s current resources permit them to explore the functions of only a limited set of genes within a limited set of physiological domains.  The purpose of this Funding Opportunity Announcement (FOA) is to expand the number of genes and range of IBD-related phenotypes and physiological domains under study by means of collaborations of the IBDGC with investigators with expertise complementary to that of their own members.  Proposed studies must not duplicate studies either ongoing or already completed by the IBDGC.  Multi-site clinical trials will not be considered responsive to this FOA.

Activities appropriate for ancillary studies include the following, as well as many others not mentioned in this list:

Visit our Institutionally Limited Submission webpage for updates and other announcements.

Research Calendar

Submit an Event

How to submit your event

See all events in the USC Research Calendar.